US benefits manager baulks after Novartis values gene therapy at $4-5 mln

* At $4-5 mln, SMA treatment would be one of industry's costliest

* Biogen's drug was first, Novartis touts a cure

* U.S. price watchdog analyzing SMA drugs for value

* Express Scripts initially baulks at lofty expectation